Insmed vs Moderna
INSM and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and MRNA compare
Moderna is the larger company, worth 3.6 times as much as Insmed ($88.5B against $24.6B).
Insmed grew revenue faster over the last twelve months (240% versus −27.6% for Moderna).
Insmed keeps more of each dollar of sales as profit, with a net margin of −39.9% compared with −141% at Moderna.
Insmed scores higher on the StockData Score (8 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | $24.6B | $88.5B |
| Share price | $112.58 | $221.72 |
| Change, 1 year | −32.6% | 798% |
| Change, 5 years | 237% | −6.4% |
| Beta (5Y) | 0.79 | 1.11 |
| Employees | 1,664 | 4,700 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.2× (better) | 39.7× |
| P/B | 33.9× | 13.1× (better) |
| FCF yield | −2.6% | −1.4% (better) |
| Fair value | $61.67 | $33.24 |
| Margin of safety | −82.5% (better) | −567% |
| Growth | ||
| Revenue growth (TTM) | 240% (better) | −27.6% |
| Revenue growth, 5Y average | 29.8% (better) | 19.3% |
| Profitability | ||
| Gross margin | 84.4% (better) | 23.4% |
| Operating margin | −37.1% (better) | −149% |
| Net margin | −39.9% (better) | −141% |
| FCF margin | −41.3% (better) | −55.8% |
| Return on equity | −72.5% | −39.0% (better) |
| Return on invested capital | – | −80.9% |
| Financial health | ||
| Debt / equity | 0.76 | 0.09 (better) |
| Interest coverage | −6.9× | – |
| Current ratio | 2.86 (better) | 2.29 |
| Altman Z-score | 6.56 | 12.86 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 79.9% |
| Held by insiders | 0.88% | 5.6% |
| Insider net buying, 12 months | −$167M | −$64.6M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.4% | 8.2% |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
- ALNY vs INSM
- BBIO vs INSM
- EXEL vs MRNA
- INSM vs IONS
- INSM vs JAZZ
- INSM vs KNSA
- INSM vs MDGL
- INSM vs RPRX
- INSM vs UTHR
For information only, not investment advice. Check the source filings before relying on any figure.